Investigating how certain gene losses affect aggressive prostate cancer
Androgen Signaling in CaP with loss of MAP3K7 and CHD1
This study is looking at how changes in two specific genes, CHD1 and MAP3K7, affect prostate cancer, especially when these genes are missing, to find new ways to treat the disease and help doctors tailor treatments to individual patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10872275 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the CHD1 and MAP3K7 genes in prostate cancer, particularly in cases where these genes are deleted. Using advanced mouse models and human cell lines, the study examines how the loss of these genes leads to more aggressive cancer characteristics and resistance to standard treatments. By identifying the downstream effects of these genetic changes, the research aims to uncover potential new therapeutic targets that could improve patient outcomes. The findings could help stratify patients based on their genetic profile, allowing for more personalized treatment approaches.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with prostate cancer who exhibit co-deletion of the CHD1 and MAP3K7 genes.
Not a fit: Patients without prostate cancer or those whose tumors do not show the specific genetic deletions being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies for men with aggressive prostate cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown that targeting genetic alterations in cancer can lead to significant advancements in treatment, suggesting a promising avenue for this approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Cramer, Scott D — University of Colorado Denver
- Study coordinator: Cramer, Scott D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.